RT Journal Article
SR Electronic
T1 Treatment of Vasomotor Symptoms
JF The Journal of the American Board of Family
                Medicine
JO J Am Board Fam Med
FD American Board of Family Medicine
SP 923
OP 932
DO 10.3122/jabfm.2023.230408R1
VO 37
IS 5
A1 Atwell, Karina
A1 White, Morgan
A1 Kuphal, Greta
A1 Williams, Makeba
A1 Schrager, Sarina
YR 2024
UL http://www.jabfm.org/content/37/5/923.abstract
AB Vasomotor symptoms (VMS) related to the menopausal transition affect the majority of women and contribute to significant quality of life burden. Incidence, length, severity and report of symptoms vary by race, ethnicity, and coexisting health conditions. The pathophysiology of VMS is not fully understood and is likely multifactorial, involving changes in the hypothalamicpituitary-ovarian axis during the menopausal transition. Treatment approaches include lifestyle modifications, hormonal and non-hormonal therapies, including integrative and complementary medicine approaches. Systemic hormone therapy with estrogen is the most effective treatment. Emerging evidence suggests that treatment with SSRIs, SNRIs, and gabapentin is effective for many women who want to avoid hormone therapy. A shared decision approach to treatment decisions involves consideration of risks with treatment options and discussion of patient priorities.